The Breast Cancer Research Center at Roswell Park Comprehensive Cancer Center is a multidisciplinary coalition of breast cancer researchers working on different pivotal topics in the field. The center serves as a central hub to better understand breast cancer across the cancer continuum, starting with disease prevention and education and continuing through advanced therapeutics and survivorship. We are committed to collaborative research that will aid the development of innovative treatments, enhance quality of life, and improve survival outcomes.
Researchers at the center employ basic, translational, and population-level approaches to interrogate risk factors, disease disparities, cancer progression, metastasis, the tumor microenvironment, and tumor metabolism. Furthering our understanding in these key areas is essential for the development of precision therapies and, ultimately, novel and effective clinical interventions.
An aspect of the research center that sets us apart from other institutions is our commitment to community engagement. We dedicated ourselves to making our findings accessible to the community to democratize information, encourage preventative lifestyle choices, and raise awareness of promising new therapies.
Research focusClinical trialsMeet our teamSupport our research
Research focus
Our researchers have expertise and special interest in the following foundational research areas. We believe these to be the frontiers of advancing treatment and improving outcomes for breast cancer patients in the Buffalo area and beyond.
Areas of research
Population studies
Addressing health disparities and risk factors to prevent and better treat the disease.
Foundational breast cancer biology
Assessing the genetic or epigenetic causes of breast cancer with a focus on fundamental properties.
Tumor evolution
Addressing mechanisms enabling the transition to metastatic disease and pathologic pro-tumorigenic changes to the tumor microenvironment.
Precision medicine
Personalized treatment approaches using individual biomarkers from advanced imaging and multiomics technologies to improve outcomes.
Tumor immunology and immunotherapy
Understanding fundamental mechanisms underlying the immune response against breast cancer and developing novel therapies to maximally unleash its tumoricidal potential.
Tumor metabolism
Determining metabolic features and dependencies to inform treatment options and expand our understanding of disease drivers.
Clinical research
Prioritizing promising translational work that provides new clinical opportunities.
Community engagement
A defining goal of the center is to engage with our community and freely disseminate our findings to aid in the understanding of breast cancer, increase awareness of risk factors associated with disease development, and highlight new developments in treatment options.
Clinical trials
Research drives the development of clinical trials, which are essential for testing new therapies and treatment approaches. Participation in clinical trials gives patients access to cutting-edge treatments that could potentially improve their outcomes. Research efforts can lead to the development of supportive care strategies that improve the overall well-being of patients undergoing treatment.
Recent publications
- Bartsch R, Pérez-García JM, Furtner J, Berghoff AS, Marhold M, Starzer AM, Hughes M, Kabraji S, Sammons S, Anders C, Murthy RK, Van Swearingen AED, Pereslete A, Gion M, Vaz Batista M, Braga S, Pinto PBC, Sampayo-Cordero M, Llombart-Cussac A, Preusser M, Cortés J, Lin NU. Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis. ESMO Open. 2025 Jan;10(1):104092. doi: 10.1016/j.esmoop.2024.104092. Epub 2025 Jan 3. PMID: 39754978; PMCID: PMC11758132.
- Dommer AP, Kumarasamy V, Wang J, O'Connor TN, Roti M, Mahan S, McLean K, Knudsen ES, Witkiewicz AK. Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer Res. 2025 Feb 13. doi: 10.1158/0008-5472.CAN-24-2244. Epub ahead of print. PMID: 39945638.
- Kumarasamy V, Wang J, Roti M, Wan Y, Dommer AP, Rosenheck H, Putta S, Trub A, Bisi J, Strum J, Roberts P, Rubin SM, Frangou C, McLean K, Witkiewicz AK, Knudsen ES. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat Commun. 2025 Feb 9;16(1):1476. doi: 10.1038/s41467-025-56674-4. PMID: 39924553; PMCID: PMC11808123.
- Das GM, Oturkar CC, Menon V. Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen? Endocrinology. 2025 Feb 5;166(3):bqaf020. doi: 10.1210/endocr/bqaf020. PMID: 39891710; PMCID: PMC11837209.
- da Silva Fernandes T, Gillard BM, Dai T, Martin JC, Chaudhry KA, Dugas SM, Fisher AA, Sharma P, Wu R, Attwood KM, Dasgupta S, Takabe K, Rosario SR, Bianchi-Smiraglia A. Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 Jan 7;15(1):1061. doi: 10.1038/s41598-024-85094-5. PMID: 39774345; PMCID: PMC11707137.
- Shi Y, McKenery A, Dolan M, Mastri M, Hill JW, Dommer A, Benzekry S, Long M, Abrams SI, Puzanov I, Ebos JML. Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors. EMBO Rep. 2025 Jan;26(2):521-559. doi: 10.1038/s44319-024-00333-0. Epub 2024 Dec 11. PMID: 39663510; PMCID: PMC11772817.
- Sharma P, Chida K, Wu R, Tung K, Hakamada K, Ishikawa T, Takabe K. VEGFA Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy. World J Oncol. 2025 Feb;16(1):120-130. doi: 10.14740/wjon1993. Epub 2025 Jan 13. PMID: 39850522; PMCID: PMC11750749.
- Yee G, Wu R, Oshi M, Endo I, Ishikawa T, Takabe K. Activity-Regulated Cytoskeleton-Associated Protein Gene Expression Is Associated With High Infiltration of Stromal Cells and Immune Cells, but With Less Cancer Cell Proliferation and Better Overall Survival in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers. World J Oncol. 2025 Feb;16(1):16-29. doi: 10.14740/wjon1936. Epub 2025 Jan 13. PMID: 39850523; PMCID: PMC11750752.
- Young J, Asaoka M, Ghasemi F, Chida K, Roy AM, Yan L, Hakamada K, Takabe K. The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition. Ann Surg Oncol. 2025 Feb 7. doi: 10.1245/s10434-025-16889-7. Epub ahead of print. PMID: 39918749.
- Huang C, Zheng E, Zheng W, Zhang H, Cheng Y, Zhang X, Shijo V, Bing RW, Komornicki I, Harris LM, Bonaccio E, Takabe K, Zhang E, Xu W, Xia J. Enhanced clinical photoacoustic vascular imaging through a skin localization network and adaptive weighting. Photoacoustics. 2025 Jan 21;42:100690. doi: 10.1016/j.pacs.2025.100690. PMID: 39916976; PMCID: PMC11800082.
- Katsuragi R, Ozturk CN, Chida K, Mann GK, Roy AM, Hakamada K, Takabe K, Satake T. Updates on Breast Reconstruction: Surgical Techniques, Challenges, and Future Directions. World J Oncol. 2024 Dec;15(6):853-870. doi: 10.14740/wjon1935. Epub 2024 Oct 6. PMID: 39697427; PMCID: PMC11650608.
- Benzekry S, Nicolò C, Mastri M, Ebos JML. Machine-learning and mechanistic modeling of primary and metastatic breast cancer growth after neoadjuvant targeted therapy. PLoS Comp Biol. 2024; 3;20(5):e1012088 PMCID: PMC11095706
- Dolan M, Shi Y, Mastri M, Long MD, McKenery A, Hill JW, Vaghi C, Benzekry S, Barbi J, Ebos JML. A senescence-mimicking (senomimetic) VEGFR TKI side-effect primes tumor immune responses via IFN/STING signaling. Mol Cancer Ther. 2024 May 1:10.1158/1535-7163.MCT-24-0139. doi: 10.1158/1535-7163.MCT-24-0139. Epub ahead of print. PMID: 38690835; PMCID: PMC11527799.
- Chua AV Jr, Sheng H, Liang E, Gandhi S, Kwan ML, Ergas IJ, Roh JM, Laurent CA, Yan L, Khoury T, Ambrosone CB, Kushi LH, Yao S. Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study. J Natl Cancer Inst. 2024 Jun 6:djae128. doi: 10.1093/jnci/djae128. Epub ahead of print. PMID: 38845078.
- Dai T, Rich LJ, Seshadri M, Dasgupta S. Protocol to detect and quantify tumor hypoxia in mice using photoacoustic imaging. STAR Protoc. 2024 Jun 21;5(2):102993. doi: 10.1016/j.xpro.2024.102993. Epub 2024 Apr 2. PMID: 38568814; PMCID: PMC10999710.
- Oturkar CC, Rosario SR, Hutson AD, Groman A, Edge SB, Morrison CD, Swetzig WM, Wang J, Park JH, Kaipparettu BA, Singh PK, Kumar S, Cappuccino HH, Ranjan M, Adjei A, Ghasemi M, Goey AKL, Kulkarni S, Das GM. ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast cancer. iScience. 2024 May 15;27(6):109995. doi: 10.1016/j.isci.2024.109995. PMID: 38868185; PMCID: PMC11166704.
- O'Connor TN, Schultz E, Wang J, O'Connor T, Levine E, Knudsen ES, Witkiewicz AK. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy. Cancers (Basel). 2024 Apr 30;16(9):1749. doi: 10.3390/cancers16091749. PMID: 38730702; PMCID: PMC11083425.
- Edge SB. Invited Commentary: Path to Omission of Axillary Surgery after Neoadjuvant Therapy for Breast Cancer. J Am Coll Surg. 2024 Mar 1;238(3):311-312. doi: 10.1097/XCS.0000000000000892. Epub 2023 Dec 5. PMID: 38050969.
- Tozbikian G, Krishnamurthy S, Bui MM, Feldman M, Hicks DG, Jaffer S, Khoury T, Wei S, Wen H, Pohlmann P. Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression. Arch Pathol Lab Med. 2024 Feb 1;148(2):242-255. doi: 10.5858/arpa.2022-0335-RA. PMID: 37014972.
- Bernicker E, Averbuch SD, Edge S, Kamboj J, Khuri FR, Pierce JY, Schiller J, Sirohi B, Thomas A, Moushey A, Phillips J, Hendricks C. Climate Change and Cancer Care: A Policy Statement From ASCO. JCO Oncol Pract. 2024 Feb;20(2):178-186. doi: 10.1200/OP.23.00637. Epub 2023 Nov 27. PMID: 38011607.
- Ochs-Balcom HM, Preus L, Du Z, Elston RC, Teerlink CC, Jia G, Guo X, Cai Q, Long J, Ping J, Li B, Stram DO, Shu XO, Sanderson M, Gao G, Ahearn T, Lunetta KL, Zirpoli G, Troester MA, Ruiz-Narváez EA, Haddad SA, Figueroa J, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Mancuso N, Press MF, Deming SL, Rodriguez-Gil JL, Yao S, Ogundiran TO, Ojengbede O, Bolla MK, Dennis J, Dunning AM, Easton DF, Michailidou K, Pharoah PDP, Sandler DP, Taylor JA, Wang Q, O'Brien KM, Weinberg CR, Kitahara CM, Blot W, Nathanson KL, Hennis A, Nemesure B, Ambs S, Sucheston-Campbell LE, Bensen JT, Chanock SJ, Olshan AF, Ambrosone CB, Olopade OI; Ghana Breast Health Study Team; Conti DV, Palmer J, García-Closas M, Huo D, Zheng W, Haiman C. Novel breast cancer susceptibility loci under linkage peaks identified in African ancestry consortia. Hum Mol Genet. 2024 Jan 23:ddae002. doi: 10.1093/hmg/ddae002. Epub ahead of print. PMID: 38263910.
- Benesch MGK, Tang X, Brindley DN, Takabe K. Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer. World J Oncol. 2024 Feb;15(1):1-13. doi: 10.14740/wjon1762. Epub 2024 Jan 20. PMID: 38274724; PMCID: PMC10807915.
- Lo Y, Lester SC, Ellis IO, Lanjewar S, Laurini J, Patel A, Bhattarai A, Ustun B, Harmon B, Kleer CG, Ross D, Amin A, Wang Y, Bradley R, Turashvili G, Zeng J, Baum J, Singh K, Hakima L, Harigopal M, Komforti M, Shin SJ, Abbott SE, Jaffer S, Badve SS, Khoury T, D'Alfonso TM, Ginter PS, Collins V, Towne W, Gan Y, Nassar A, Sahin AA, Flieder A, Aldrees R, Ngo MH, Edema U, Sapna F, Schnitt SJ, Fineberg SA. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Arch Pathol Lab Med. 2024 Jan 20. doi: 10.5858/arpa.2023-0163-OA. Epub ahead of print. PMID: 38244086.
- Hook C, Chatterjee U, Sheng H, Zhu Q, Robinson T, Roh JM, Laurent CA, Lee C, Delmerico J, Lo JC, Ambrosone CB, Kushi LH, Kwan ML, Yao S. A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors. NPJ Breast Cancer. 2024 Jan 20;10(1):9. doi: 10.1038/s41523-024-00615-9. PMID: 38245540; PMCID: PMC10799916.
- Holling GA, Chavel CA, Sharda AP, Lieberman MM, James CM, Lightman SM, Tong JH, Qiao G, Emmons TR, Giridharan T, Hou S, Intlekofer AM, Higashi RM, Fan TWM, Lane AN, Eng KH, Segal BH, Repasky EA, Lee KP, Olejniczak SH. CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity. Cell Mol Immunol. 2024 Jan 18. doi: 10.1038/s41423-024-01124-2. Epub ahead of print. PMID: 38233562.
- Nelson ED, Benesch MG, Wu R, Ishikawa T, Takabe K. High EIF4EBP1 expression reflects mTOR pathway activity and cancer cell proliferation and is a biomarker for poor breast cancer prognosis. Am J Cancer Res. 2024 Jan 15;14(1):227-242. PMID: 38323277; PMCID: PMC10839327.
- Tzetzo SL, Kramer ED, Mohammadpour H, Kim M, Rosario SR, Yu H, Dolan MR, Oturkar CC, Morreale BG, Bogner PN, Stablewski AB, Benavides FJ, Brackett CM, Ebos JML, Das GM, Opyrchal M, Nemeth MJ, Evans SS, Abrams SI. Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression. iScience. 2024 Feb 10;27(3):109187. doi: 10.1016/j.isci.2024.109187. PMID: 38420590; PMCID: PMC10901102.
- Martin JC, da Silva Fernandes T, Chaudhry KA, Oshi M, Abrams SI, Takabe K, Rosario SR, Bianchi-Smiraglia A. Aryl hydrocarbon receptor suppresses STING-mediated type I IFN expression in triple-negative breast cancer. Sci Rep. 2024 Mar 8;14(1):5731. doi: 10.1038/s41598-024-54732-3. PMID: 38459088; PMCID: PMC10923803.
- Wu R, Horimoto Y, Oshi M, Benesch MGK, Khoury T, Takabe K, Ishikawa T. Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Jpn J Clin Oncol. 2024 Mar 23:hyae033. doi: 10.1093/jjco/hyae033. Epub ahead of print. PMID: 38521965.
- Poole RA, Wang Q, Ray A, Takabe K, Opyrchal M, Katsuta E. Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients. Cancers (Basel). 2024 Feb 6;16(4):683. doi: 10.3390/cancers16040683. PMID: 38398074; PMCID: PMC10887014.
- Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, Hershman DL, Unger JM, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Netw Open. 2023 May 1;6(5):e2311673. doi: 10.1001/jamanetworkopen.2023.11673. PMID: 37140922; PMCID: PMC10160875.
- Scarpetti L, Oturkar CC, Juric D, Shellock M, Malvarosa G, Post K, Isakoff S, Wang N, Nahed B, Oh K, Das GM, Bardia A. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. Oncologist. 2023 Apr 6;28(4):358-363. doi: 10.1093/oncolo/oyac281. PMID: 36772966; PMCID: PMC10078911.
- Wang W, Ling X, Wang R, Xiong H, Hu L, Yang Z, Wang H, Zhang Y, Wu W, Singh PK, Wang J, Li F, Li Q. Structure-Activity Relationship of FL118 Platform Position 7 Versus Position 9-Derived Compounds and Their Mechanism of Action and Antitumor Activity. J Med Chem. 2023 Dec 28;66(24):16888-16916. doi: 10.1021/acs.jmedchem.3c01589. Epub 2023 Dec 15. PMID: 38100041.
- Kwan ML, Valice E, Ergas IJ, Roh JM, Caan BJ, Cespedes Feliciano EM, Kolevska T, Hartman TJ, Quesenberry CP Jr, Ambrosone CB, Kushi LH. Alcohol consumption and prognosis and survival in breast cancer survivors: The Pathways Study. Cancer. 2023 Dec 15;129(24):3938-3951. doi: 10.1002/cncr.34972. Epub 2023 Aug 9. PubMed PMID: 37555890; PubMed Central PMCID: PMC10840903.
- Tjader NP, Beer AJ, Ramroop J, Tai MC, Ping J, Gandhi T, Dauch C, Neuhausen SL, Ziv E, Sotelo N, Ghanekar S, Meadows O, Paredes M, Gillespie J, Aeilts A, Hampel H, Zheng W, Jia G, Hu Q, Wei L, Liu S, Ambrosone CB, Palmer JR, Carpten JD, Yao S, Stevens P, Ho WK, Pan JW, Fadda P, Huo D, Teo SH, McElroy JP, Toland AE. Association of ESR1 germline variants with TP53 somatic variants in breast tumors in a genome-wide study. medRxiv [Preprint]. 2023 Dec 6:2023.12.06.23299442. doi: 10.1101/2023.12.06.23299442. PMID: 38106140; PMCID: PMC10723566.
- Ergas IJ, Bradshaw PT, Cespedes Feliciano EM, Roh JM, Kwan ML, Laraia B, Madsen KA, Yao S, Thomsen C, Kushi LH. Hypothetical Interventions on Diet Quality and Lifestyle Factors to Improve Breast Cancer Survival: The Pathways Study. Cancer Epidemiol Biomarkers Prev. 2023 Dec 1;32(12):1716-1725. doi: 10.1158/1055-9965.EPI-22-1216. PubMed PMID: 37721486; PubMed Central PMCID: PMC10841733.
- Gelman IH. Metastasis suppressor genes in clinical practice: are they druggable? Cancer Metastasis Rev. 2023 Dec;42(4):1169-1188. doi: 10.1007/s10555-023-10135-w. Epub 2023 Sep 25. PMID: 37749308.
- Patel RK, Frankel L, Cardeiro M, Hansen W, Takabe K, Rashid OM. The Role of Crohn Disease on Breast Cancer Incidence: A Clinical Analysis. World J Oncol. 2023 Dec;14(6):457-463. doi: 10.14740/wjon1644. Epub 2023 Oct 21. PMID: 38022407; PMCID: PMC10681792.
- Vylegzhanina AV, Bespalov IA, Novototskaya-Vlasova KA, Hall BM, Gleiberman AS, Yu H, Leontieva OV, Leonova KI, Kurnasov OV, Osterman AL, Dy GK, Komissarov AA, Vasilieva E, Gehlhausen J, Iwasaki A, Ambrosone CB, Tsuji T, Matsuzaki J, Odunsi K, Andrianova EL, Gudkov AV. Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans. Cancer Res Commun. 2023 Nov 8;3(11):2256-2267. doi: 10.1158/2767-9764.CRC-23-0289. PMID: 37870410; PMCID: PMC10631453.
- Roy AM, Patel A, Catalfamo K, Attwood K, Khoury T, Yao S, Gandhi S. Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer. JAMA Netw Open. 2023 Nov 1;6(11):e2344517. doi: 10.1001/jamanetworkopen.2023.44517. PMID: 37991763; PMCID: PMC10665980.
- Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx. J Immunother Cancer. 2023 Nov;11(11):e007381. doi: 10.1136/jitc-2023-007381. PMID: 37963636; PMCID: PMC10649898.
- Roy AM, George A, Attwood K, Alaklabi S, Patel A, Omilian AR, Yao S, Gandhi S. Effect of neighborhood deprivation index on breast cancer survival in the United States. Breast Cancer Res Treat. 2023 Nov;202(1):139-153. doi: 10.1007/s10549-023-07053-4. Epub 2023 Aug 5. PubMed PMID: 37542631; PubMed Central PMCID: PMC10504126.
- Chen CS, Zirpoli G, Barlow WE, Budd GT, McKiver B, Pusztai L, Hortobagyi GN, Albain KS, Damaj MI, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. J Natl Compr Canc Netw. 2023 Nov;21(11):1172-1180.e3. doi: 10.6004/jnccn.2023.7062. PMID: 37935109.
- Wu R, Oshi M, Asaoka M, Yan L, Benesch MGK, Khoury T, Nagahashi M, Miyoshi Y, Endo I, Ishikawa T, Takabe K. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer. Ann Surg. 2023 Oct 1;278(4):587-597. doi: 10.1097/SLA.0000000000005954. Epub 2023 Jun 15. PubMed PMID: 37318852; PubMed Central PMCID: PMC10481934.
- Allen CJ, Snyder RA, Horn DM, Hudson MF, Barber A, Smieliauskas F, Spears PA, Edge S, Greenup RA. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey. JCO Oncol Pract. 2023 Oct;19(10):932-938. doi: 10.1200/OP.23.00159. Epub 2023 Aug 31. PMID: 37651652; PMCID: PMC10615548.
- Takeshita T, Iwase H, Wu R, Ziazadeh D, Yan L, Takabe K. Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature. World J Oncol. 2023 Oct;14(5):406-422. doi: 10.14740/wjon1700. Epub 2023 Sep 20. PMID: 37869243; PMCID: PMC10588506.
- Hagerty BL, Takabe K. Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. World J Oncol. 2023 Oct;14(5):340-349. doi: 10.14740/wjon1655. Epub 2023 Sep 20. PMID: 37869242; PMCID: PMC10588497.
- Moro K, Ichikawa H, Koyama Y, Abe S, Uchida H, Naruse K, Obata Y, Tsuchida J, Toshikawa C, Ikarashi M, Muneoka Y, Miura K, Tajima Y, Shimada Y, Kobayashi T, Sakata J, Takabe K, Wakai T. Oral Administration of Glucosylceramide Suppresses Tumor Growth by Affecting the Ceramide/Sphingosine-1-Phosphate Balance in Breast Cancer Tissue. World J Oncol. 2023 Oct;14(5):430-437. doi: 10.14740/wjon1656. Epub 2023 Sep 20. PMID: 37869237; PMCID: PMC10588502.
- Kumarasamy V, Gao Z, Zhao B, Jiang B, Rubin SM, Burgess K, Witkiewicz AK, Knudsen ES. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies. Br J Cancer. 2023 Oct;129(8):1238-1250. doi: 10.1038/s41416-023-02399-4. Epub 2023 Aug 25. PMID: 37626264; PMCID: PMC10575895.
- Liu T, Zhou J, Chen Y, Fang J, Liu S, Frangou C, Wang H, Zhang J. Genome-Wide Characterization of TAZ Binding Sites in Mammary Epithelial Cells. Cancers (Basel). 2023 Sep 25;15(19). doi: 10.3390/cancers15194713. PubMed PMID: 37835407; PubMed Central PMCID: PMC10571831.
- Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ Precis Oncol. 2023 Sep 13;7(1):90. doi: 10.1038/s41698-023-00438-0. PMID: 37704753; PMCID: PMC10499925.
- Ilozumba MN, Yaghjyan L, Datta S, Zhao J, Hong CC, Lunetta KL, Zirpoli G, Bandera EV, Palmer JR, Yao S, Ambrosone CB, Cheng TD. mTOR pathway candidate genes and energy intake interaction on breast cancer risk in Black women from the Women's Circle of Health Study. Eur J Nutr. 2023 Sep;62(6):2593-2604. doi: 10.1007/s00394-023-03176-y. Epub 2023 May 20. PubMed PMID: 37209192; PubMed Central PMCID: PMC10695182.
In the news
Looking for research experience?
Are you a high school, undergraduate, or medical student interested in gaining research experience? Check out the immersive research programs we offer to get involved in the exciting research at Roswell Park.
The Breast Cancer Research Center serves as a ‘public square’ to enable discussions between clinicians and researchers alike about their latest and greatest findings. It encourages us all to ask how we can work better as a concerted team toward a shared goal – curing breast cancer.Thomas O'Connor, PhD, Breast Cancer Research Center Coordinator
Contact us
Thomas O'Connor, PhD
Coordinator, Roswell Park Breast Cancer Research Center
Roswell Park Comprehensive Cancer Center
Elm & Carlton Streets
Buffalo, NY 14263
Thomas.O'Connor@RoswellPark.org
Elm & Carlton Streets
Buffalo, NY 14263
Thomas.O'Connor@RoswellPark.org